OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Sep 11, 2023 • 16min
S9 Ep25: Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities
Dr Fonkoua discusses the ways in which common clinical trial enrollment criteria in oncology exclude patients from underrepresented groups, enrollment disparities that uniquely affect patients with liver cancer, and initiatives that Mayo Clinic is participating in to eliminate barriers to clinical trial enrollment.
Sep 7, 2023 • 15min
S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.
Sep 4, 2023 • 15min
S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Dr. Usmani discusses the use of bispecific antibodies in treating relapsed/refractory multiple myeloma, emphasizing their integration into current management strategies. Topics include adverse effects, supportive care, patient selection, dosing considerations, toxicity management, and ongoing research for improved treatment outcomes.
Aug 31, 2023 • 14min
S9 Ep22: Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC
Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.
Aug 28, 2023 • 12min
S9 Ep21: FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.
Aug 21, 2023 • 11min
S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML
Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.
Aug 17, 2023 • 8min
S9 Ep19: Trent Breaks Down Mutation Testing and ctDNA Monitoring in GIST
Dr Trent discusses the need for improved awareness around mutation testing in GIST, the limitations of current clinical trial criteria, and the potential for ctDNA to become a longitudinal cancer monitoring tool, helping to prevent invasive means of measuring disease progression.
Aug 14, 2023 • 14min
S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why uproleselan could affect the treatment paradigm across AML subtypes, and the rationale for pursuing minimal residual disease negativity as a clinical end point in AML.
Aug 10, 2023 • 20min
S9 Ep17: Sanai Spotlights Meningioma Symptoms, Treatment Options, and Research Needs
Dr Sanai discusses the prevalence and grading of malignant meningiomas; common symptoms associated with these tumors; treatment modalities for high-grade disease; and more.
Aug 7, 2023 • 15min
S9 Ep16: Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCINTIX biology-guided technology; and how John Theurer Cancer Center plans to use this technology and help advance its role in the field of radiation oncology.
